Octopus Titan VCT 2 PLC: Issue of Equity and To...
Octopus Titan VCT 2 PLC: Issue of Equity and Total Voting Rights
The Company announces that on 5 April 2014, 151,706 Ordinary Shares of 10p each were issued and allotted at a price of 97p per share pursuant to the Offer for Subscription (the "Offer") that opened on 4 April 2014. The Offer in respect of the 2013/2014 tax year closed at 12 noon today (5 April 2014).
Application has been made to the London Stock Exchange for admission of the new shares. Admission is expected to become effective on or around 18 April 2014.
The issued share capital and total voting rights of the Company is now: 32,145,897 Ordinary Shares.
For further information please contact:
Patricia Standaloft Company Secretary 0207 710 6471
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Octopus Titan VCT 2 PLC via Globenewswire
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.